Cover Image
市場調查報告書

原發性顫抖症:開發中產品分析

Essential Tremor - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 362368
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
原發性顫抖症:開發中產品分析 Essential Tremor - Pipeline Review, H2 2016
出版日期: 2016年12月14日 內容資訊: 英文 48 Pages
簡介

本報告提供原發性顫抖症治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

原發性顫抖症概要

治療藥的開發

  • 開發中產品的概要

原發性顫抖症:企業開發中的治療藥

原發性顫抖症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

原發性顫抖症:企業開發中的產品

原發性顫抖症的治療藥的開發企業

  • Merz GmbH & Co. KGaA
  • Neurocrine Biosciences, Inc.
  • Sage Therapeutics, Inc.

原發性顫抖症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

原發性顫抖症:最近的開發平台趨勢

原發性顫抖症:暫停中的計劃

原發性顫抖症:開發中止的產品

原發性顫抖症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8799IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Tremor - Pipeline Review, H2 2016, provides an overview of the Essential Tremor (Central Nervous System) pipeline landscape.

Essential tremor is a type of involuntary shaking movement in which no cause can be identified. Involuntary means you shake without trying to do so. Essential tremor is the most common type of tremor. The exact cause for essential tremor is unknown. Tremors occur when there is a problem with the nerves that supply certain muscles. The tremor is more likely to be noticed in the hands, but may affect the arms, head, eyelids, or other muscles. The tremor rarely affects the legs or feet. Treatment may not be needed unless the tremors interfere with your daily activities or cause embarrassment.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Essential Tremor - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Essential Tremor (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Tremor (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Essential Tremor and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Discovery stages are 2, 2 and 2 respectively.Essential Tremor.

Essential Tremor (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Tremor (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Essential Tremor (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Essential Tremor (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Essential Tremor (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Essential Tremor (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Essential Tremor (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Essential Tremor (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Essential Tremor Overview
  • Therapeutics Development
    • Pipeline Products for Essential Tremor - Overview
  • Essential Tremor - Therapeutics under Development by Companies
  • Essential Tremor - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Essential Tremor - Products under Development by Companies
  • Essential Tremor - Companies Involved in Therapeutics Development
    • Merz Pharma GmbH & Co KgaA
    • Neurocrine Biosciences Inc
    • Sage Therapeutics Inc
  • Essential Tremor - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • incobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NBI-640756 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sepranolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Essential Tremor - Dormant Projects
  • Essential Tremor - Discontinued Products
  • Essential Tremor - Product Development Milestones
    • Featured News & Press Releases
      • Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting
      • Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
      • Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor
      • Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Essential Tremor, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Essential Tremor - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2016
  • Essential Tremor - Pipeline by Neurocrine Biosciences Inc, H2 2016
  • Essential Tremor - Pipeline by Sage Therapeutics Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Essential Tremor - Dormant Projects, H2 2016
  • Essential Tremor - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Essential Tremor, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top